Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06018987
Other study ID # M21-833
Secondary ID
Status Active, not recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date September 5, 2023
Est. completion date August 19, 2026

Study information

Verified date June 2024
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nasolabial folds (NLF) are the two skin folds that run from each side of the nose to the corners of the mouth. Prominent NLFs distort the contour of the midface, giving a fatigued and aged appearance. Soft tissue fillers can be used to reduce the depth of NLFs and restore a more youthful appearance. The purpose of this study is to evaluate how safe and effective HAC 20L is in the correction of moderate to severe NLF in adult participants. HAC 20L is an investigational drug being developed for the treatment of NLF. There are 2 cohorts in this study. In each cohort participants are assigned to either the treatment group or no-treatment control group. There is a 1 in 3 chance that participants will be assigned to the no-treatment control group. Around 255 adult participants with moderate to severe NLF will be enrolled in the study at approximately 20 sites worldwide. Participants in the treatment group will receive an injection of HAC 20L to the NLF on Day 1 in Cohort 1 and Cohort 2 with the option of re-treatment after completion of Month 12 visit. The control group will receive no treatment but will be offered an optional HAC 20L treatment after 6 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be examined by completing effectiveness questionnaires by the subjects, evaluating investigator (EI) and central reviewers as well as monitoring safety assessments such as vital signs, blood tests, injection site responses and adverse events.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No-Treatment Control
Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
Device:
HAC 20L
Subdermal Injections

See more »

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Achieving Responder Status Based on Evaluating Investigator's (EI's) Live Assessment of Nasolabial Folds (NLF) Severity using the Nasolabial Fold Severity Scale (NLFSS) The NLFSS is a 5-point photonumeric scale used by the EI to assess the severity of each NFL where 0 = None and 4 = Extreme. A responder is defined as a participant who shows at least 1-point improvement on the NLFSS from baseline on both sides. Month 6
Primary Number of Participants with Adverse Events (AEs) An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this device Month 16
Secondary Change from Baseline on the Overall Score of FACE-Q-Appraisal of Lines: Nasolabial Folds Questionnaire The FACE Q-Appraisal of lines: Nasolabial Folds consists of 5 questions to assess how much the participants has been bothered by various aspects of NLFs in the past week where 1 = not at all and 4 = extremely. Baseline to Month 6
Secondary Percentage of Participants Achieving Responder Status Based on Evaluating Investigator's Assessment of Global Aesthetic Improvement on the NLF Area using the Global Aesthetic Improvement Scale (GAIS) The GAIS will assess global aesthetic improvement of the NLF area by comparing the frontal and side view photographs taken at baseline where -2 = Much Worse and 2 = Much Improved. A responder is defined as achieving "improved" or "much improved". Month 6
Secondary Percentage of Participants Achieving Responder Status Based on Participant's Assessment of Global Aesthetic Improvement in the NLF Area Using the GAIS The GAIS will assess global aesthetic improvement of the NLF area by comparing the frontal and side view photographs taken at baseline where -2 = Much Worse and 2 = Much Improved. A responder is defined as achieving "improved" or "much improved". Month 6
See also
  Status Clinical Trial Phase
Completed NCT01115634 - Autologous Fibroblast Transplantation in Facial Deformities Phase 2
Completed NCT01012661 - Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler Phase 4
Completed NCT00778531 - Protocol for the Post-approval Study of ArteFill® for Correction of Nasolabial Folds Phase 4
Completed NCT03932045 - A Study to Evaluate the Safety and Efficacy of SYB Filler(SF-01) in the Correction of Nasolabial Folds N/A
Completed NCT02647853 - Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Phase 1
Completed NCT01069354 - Evaluation of Pain With Radiesse® With Lidocaine for Nasolabial Folds N/A
Completed NCT00850889 - Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nasolabial Folds Phase 4
Completed NCT00797459 - Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds N/A
Recruiting NCT06093321 - A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement N/A
Not yet recruiting NCT06295172 - A Study Comparing Lafullen15 and Lafullen for Temporary Nasolabial Fold Improvement N/A
Completed NCT01060943 - An Efficacy and Safety Study of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds Phase 3
Completed NCT05612958 - Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds N/A
Completed NCT02672644 - Non-comparative Evaluation of Facial Expressions Following Lower Face Correction Using Emervel Classic and Emervel Deep Phase 4
Completed NCT01012388 - Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color Phase 4
Completed NCT01635855 - Belotero Post Approval Study Phase 4
Completed NCT02179736 - A Post Market Evaluation After Treatment of Nasolabial Folds N/A
Terminated NCT00716443 - Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections Phase 4
Recruiting NCT02607670 - Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds Phase 2
Completed NCT00823069 - Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose N/A
Recruiting NCT06367634 - TEOSYAL® PureSense ULTRA DEEP Versus Restylane® Lidocaine for the Correction of Moderate to Severe Nasolabial Folds in Chinese Adults N/A

External Links